ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
| Revenue (TTM) | $509.86M |
| Gross Profit (TTM) | $312.42M |
| EBITDA | $214.82M |
| Operating Margin | -123.40% |
| Return on Equity | 43.30% |
| Return on Assets | 22.00% |
| Revenue/Share (TTM) | $2.14 |
| Book Value | $1.68 |
| Price-to-Book | 5.31 |
| Price-to-Sales (TTM) | 4.16 |
| EV/Revenue | 4.198 |
| EV/EBITDA | 9.66 |
| Quarterly Earnings Growth (YoY) | -52.80% |
| Quarterly Revenue Growth (YoY) | 15.90% |
| Shares Outstanding | $231.77M |
| Float | $226.72M |
| % Insiders | 1.87% |
| % Institutions | 93.94% |
Volatility is currently expanding
New class action for ADMA Biologics (ADMA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/10/2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW ORLEANS, La., July 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) (“ADMA” or the “Company”), if they purchased or otherwise acquired the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) of the August 10, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The ADMA Class Action Lawsuit : Do you, or did you, own shares of ADMA Biologics, Inc. (NASDAQ: ADMA)?
SAN DIEGO, July 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 8, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
ADMA Biologics projected 20% ASCENIV revenue growth in 2025, but a short-seller report alleges the real figure was a 3% decline, with the gap driven entirely by an alleged channel stuffing scheme. NEW YORK, July 8, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP highlights the contrast between ADMA Biologics, Inc.'s (NASDAQ: ADMA) public growth projections and the results alleged by independent research.
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.
ADMA Biologics Investors that Lost Money after Channel Stuffing Allegations are Notified to Contact BFA Law about the Filed Securities Fraud Class Action
